Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Mylan CEO intent on new global biz
The rise of generic drugs has been bad news for Big Pharma, but not so bad for copycat makers like Mylan, which gets the profile treatment today from its hometown newspaper, the Pittsburgh Tribune-Review. Since Labor Day five stock analysts have upgraded their ratings on the company, which bought Merck KGaA's worldwide generics unit in October for $7.4 billion. And that deal followed January's big investment in India's Matrix Pharmaceutical Laboratories. With those buys, Mylan became the world's third-largest generics maker. "I thought global from day one," CEO Robert J. Coury told the newspaper.
One interesting note: To embark on his growth plan, Coury had to squeeze out one of the company's big investors, none other than Carl Icahn. Might some Icahn-burdened biopharmas do the same?
- read more from Mylan's CEO in the Tribune-Review
Related Articles:
Pharma faces "tidal wave" of generics. Report
Patent 'cliff' looms for Big Pharma. Report
Glaxo to let Mylan make generic Paxil. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
